Autor: |
José J. Valdés-Aguayo, Idalia Garza-Veloz, José R. Vargas-Rodríguez, María C. Martinez-Vazquez, Lorena Avila-Carrasco, Sofia Bernal-Silva, Carolina González-Fuentes, Andreu Comas-García, Diana E. Alvarado-Hernández, Alba S. H. Centeno-Ramirez, Iram P. Rodriguez-Sánchez, Ivan Delgado-Enciso, Margarita L. Martinez-Fierro |
Jazyk: |
angličtina |
Rok vydání: |
2021 |
Předmět: |
|
Zdroj: |
Frontiers in Cellular and Infection Microbiology, Vol 11 (2021) |
Druh dokumentu: |
article |
ISSN: |
2235-2988 |
DOI: |
10.3389/fcimb.2021.754708 |
Popis: |
IntroductionDuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the virus hijacks the mitochondria causing damage of its membrane and release of mt-DNA into the circulation which can trigger innate immunity and generate an inflammatory state. In this study, we explored the importance of peripheral blood mt-DNA as an early predictor of evolution in patients with COVID-19 and to evaluate the association between the concentration of mt-DNA and the severity of the disease and the patient’s outcome.MethodsA total 102 patients (51 COVID-19 cases and 51 controls) were included in the study. mt-DNA obtained from peripheral blood was quantified by qRT-PCR using the NADH mitochondrial gene.ResultsThere were differences in peripheral blood mt-DNA between patients with COVID-19 (4.25 ng/μl ± 0.30) and controls (3.3 ng/μl ± 0.16) (p = 0.007). Lower mt-DNA concentrations were observed in patients with severe COVID-19 when compared with mild (p= 0.005) and moderate (p= 0.011) cases of COVID-19. In comparison with patients with severe COVID-19 who survived (3.74 ± 0.26 ng/μl) decreased levels of mt-DNA in patients with severe COVID-19 who died (2.4 ± 0.65 ng/μl) were also observed (p = 0.037).ConclusionHigh levels of mt-DNA were associated with COVID-19 and its decrease could be used as a potential biomarker to establish a prognosis of severity and mortality of patients with COVID-19. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|